FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891640184> ?p ?o ?g. }

• W2891640184 endingPage "e15046" @default.
• W2891640184 startingPage "e15046" @default.
• W2891640184 abstract "e15046 Background: COX-2 inhibition or aspirin use increase colorectal cancer survival by affecting tumor microenvironment through PD-1/PDL-1 pathway. Optimal use of these agents in cancer is unknown. We reported that maintenance ADAPT with capecitabine and celecoxib ± radiation following first-line chemotherapy results in higher complete response (CR) rate and prolong survival in stage IV colorectal cancer patients and we updated ten-year survival outcomes from two major cancer centers. Methods: IRB approved this UW study. We pooled MDACC database with theUW database constructed by searching Clinical Data Repository using Amalga. Cases and controls were found in the note. Clinical data elements were extracted from various data sources within the repository. Automated parsing of notes and reports was employed to extract several key variables to match the data from earlier MDACC database. Independent manual quality control was also conducted and records verified. Results: Pooled database included 437 patients treated with (A) capecitabine and celecoxib (N = 195) including 28 pts enrolled ongoing phase II trial (NCT01729923), (B) capecitabine bevacizumab (N = 241) and 93/195 in the capecitabine and celecoxib were deemed to have achieved complete responses with or without surgery whereas 63 of 241 patients had achieved complete responses. Median Survival from CRC diagnosis date was 74.9 months (A) versus 33 months (B) (p < 0.001). Median Survival from stage IV was 57.8 months (A) versus 24 months (B) and 21 months (C) (p < 0.001). Median survival of 93 complete responders from no surgery (N = 51) versus surgical (N = 42) was 75 vs 57 months from stage IV onset and 87 vs 68 months from CRC diagnosis respectively. Our omics models suggest that ADAPT therapy boost immune surveillance by up-regulating PDL-1 which paradoxically improved CRC survival. Conclusions: Capecitabine and celecoxib after first-line chemotherapy demonstrated durable complete response and significant better survival noted in none surgical CR patients versus surgically resected patients. Abscopal effects of radiation may contribute to CR and survival. Further randomized studies on the ADAPT strategy are warranted. Clinical trial information: NCT01729923." @default.
• W2891640184 created "2018-09-27" @default.
• W2891640184 creator A5006150283 @default.
• W2891640184 creator A5016787975 @default.
• W2891640184 creator A5019508460 @default.
• W2891640184 creator A5046875386 @default.
• W2891640184 creator A5050227665 @default.
• W2891640184 creator A5052267007 @default.
• W2891640184 creator A5066957198 @default.
• W2891640184 creator A5072866393 @default.
• W2891640184 creator A5087491523 @default.
• W2891640184 date "2016-05-20" @default.
• W2891640184 modified "2023-09-27" @default.
• W2891640184 title "ADAPT therapy vs capecitabine bevacizumab in stage IV colorectal cancer: Pooled 10-year survival experience and a phase II study update." @default.
• W2891640184 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.e15046" @default.
• W2891640184 hasPublicationYear "2016" @default.
• W2891640184 type Work @default.
• W2891640184 sameAs 2891640184 @default.
• W2891640184 citedByCount "1" @default.
• W2891640184 countsByYear W28916401842019 @default.
• W2891640184 crossrefType "journal-article" @default.
• W2891640184 hasAuthorship W2891640184A5006150283 @default.
• W2891640184 hasAuthorship W2891640184A5016787975 @default.
• W2891640184 hasAuthorship W2891640184A5019508460 @default.
• W2891640184 hasAuthorship W2891640184A5046875386 @default.
• W2891640184 hasAuthorship W2891640184A5050227665 @default.
• W2891640184 hasAuthorship W2891640184A5052267007 @default.
• W2891640184 hasAuthorship W2891640184A5066957198 @default.
• W2891640184 hasAuthorship W2891640184A5072866393 @default.
• W2891640184 hasAuthorship W2891640184A5087491523 @default.
• W2891640184 hasConcept C121608353 @default.
• W2891640184 hasConcept C126322002 @default.
• W2891640184 hasConcept C141071460 @default.
• W2891640184 hasConcept C143998085 @default.
• W2891640184 hasConcept C146357865 @default.
• W2891640184 hasConcept C151730666 @default.
• W2891640184 hasConcept C2776467144 @default.
• W2891640184 hasConcept C2776694085 @default.
• W2891640184 hasConcept C2777802072 @default.
• W2891640184 hasConcept C2777909004 @default.
• W2891640184 hasConcept C526805850 @default.
• W2891640184 hasConcept C71924100 @default.
• W2891640184 hasConcept C86803240 @default.
• W2891640184 hasConceptScore W2891640184C121608353 @default.
• W2891640184 hasConceptScore W2891640184C126322002 @default.
• W2891640184 hasConceptScore W2891640184C141071460 @default.
• W2891640184 hasConceptScore W2891640184C143998085 @default.
• W2891640184 hasConceptScore W2891640184C146357865 @default.
• W2891640184 hasConceptScore W2891640184C151730666 @default.
• W2891640184 hasConceptScore W2891640184C2776467144 @default.
• W2891640184 hasConceptScore W2891640184C2776694085 @default.
• W2891640184 hasConceptScore W2891640184C2777802072 @default.
• W2891640184 hasConceptScore W2891640184C2777909004 @default.
• W2891640184 hasConceptScore W2891640184C526805850 @default.
• W2891640184 hasConceptScore W2891640184C71924100 @default.
• W2891640184 hasConceptScore W2891640184C86803240 @default.
• W2891640184 hasIssue "15_suppl" @default.
• W2891640184 hasLocation W28916401841 @default.
• W2891640184 hasOpenAccess W2891640184 @default.
• W2891640184 hasPrimaryLocation W28916401841 @default.
• W2891640184 hasRelatedWork W1497385339 @default.
• W2891640184 hasRelatedWork W2051540233 @default.
• W2891640184 hasRelatedWork W2092651826 @default.
• W2891640184 hasRelatedWork W2145753255 @default.
• W2891640184 hasRelatedWork W2417717847 @default.
• W2891640184 hasRelatedWork W2587632802 @default.
• W2891640184 hasRelatedWork W2602417212 @default.
• W2891640184 hasRelatedWork W349909140 @default.
• W2891640184 hasRelatedWork W4230554002 @default.
• W2891640184 hasRelatedWork W4251132435 @default.
• W2891640184 hasVolume "34" @default.
• W2891640184 isParatext "false" @default.
• W2891640184 isRetracted "false" @default.
• W2891640184 magId "2891640184" @default.
• W2891640184 workType "article" @default.